^
    Back
    Association details:
    Biomarker:EGFR wild-type + ALK wild-type
    Cancer:Non Small Cell Lung Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors

    Excerpt:
    ...EGFR and ALK wild type...
    Trial ID:
    NCT03656094
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Immunother Precis Oncol
    Title:

    Treatment of Stage IV Non–Small Cell Lung Cancer with Pembrolizumab in Combination with Platinum-Based Doublet Chemotherapy in Vietnam

    Published date:
    08/07/2023
    Excerpt:
    Treatment of stage IV non–small cell lung cancer without EGFR and ALK gene mutations with the immunotherapy protocol of pembrolizumab in combination with platinum-based doublet chemotherapy resulted in favorable outcomes without any new safety concerns.
    Secondary therapy:
    Chemotherapy
    DOI:
    https://doi.org/10.36401/JIPO-23-12